GS-1427 / Gilead 
Welcome,         Profile    Billing    Logout  

3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GS-1427 / Gilead
SWIFT, NCT06290934: Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
423
US
GS-1427, Ustekinumab, Placebo-to-match GS-1427
Gilead Sciences
Ulcerative Colitis
05/27
03/28
ACTRN12621000612819p: A Phase 1, Dose-Escalation Study in Healthy Volunteers to Evaluate the Pharmacokinetics, Safety, and Tolerability of GS-1427 Following Single and Multiple Dosing

Not yet recruiting
1
110
 
Gilead Sciences, Gilead Sciences
Inflammatory bowel disease
 
 
ACTRN12621000612819: A Phase 1, Dose-Escalation Study in Healthy Volunteers to Evaluate the Pharmacokinetics, Safety, and Tolerability of GS-1427 Following Single and Multiple Dosing

Completed
1
110
 
Gilead Sciences, Gilead Sciences
Inflammatory bowel disease
 
 

Download Options